Mice that were treated with celecoxib during the initial infection had significantly increased bacterial burdens in lungs (Fig. 3b) and spleen (Supplementary Fig. 4A) when their second infection progressed from week 3 to week 6, indicating that the COXi-effect was long-lasting and independent on ongoing celecoxib treatment (p < 0.0001 and p = 0.0015, respectively). This evidence concerns the gene MT-CO1 and infection.